5th International Conference on
Toxicology and Clinical Toxicology

Professor Kattesh V. Katti has internationally recognized as a leader in the interconnecting fields of— chemistry, radiopharmaceutical sciences, nanotechnology/green nanotechnology, and nanomedicine— for biomedical applications, specifically for molecular imaging and therapy of living subjects. The impact of Dr. Kattiâ s work is widespread, as his pioneering discoveries and strategies, originally developed in his laboratory in bioconjugate chemistry and Nanomedicine, and green nanotechnological tools, are used in many laboratories, industries, and hospitals around the world. His contributions to nano and green nanotechnologies have already created transformative progress in nanomedicine by aiding molecular imaging to help diagnose and manage therapy— all at the cellular levels. Dr. Kattiâ s groundbreaking discoveries in green nanotechnology where he has demonstrated that biocompatible nanoparticles can be produced without the intervention of any toxic chemicals, through phytochemicals of high antioxidant capacities and tumor receptor specificities have created a new generation of molecular imaging and therapeutic nanoceuticals. His approach to green nanotechnology has furthered the scope of holistic and integrative medicine with implications in modulating signaling pathways allowing optimization of therapies targeted to tumor cells/regions without causing adverse toxic effects to normal cells. These original discoveries are expected to have a major impact on how molecular imaging and therapies will eventually be individualized to allow their greater success through theranostic approaches using radioactive nanoparticles, photothermal therapy using targeted nanoparticles, and novel therapies involving phytochemicals. A myriad of such approaches developed by Dr. Katti is already impacting clinical translation through comparative oncology in realistic ways as new drugs are being validated for their efficacy in imaging and therapy using tumor-bearing dogs where the disease mimics human conditions. In recognition of his original contributions, Dr. Katti has been awarded several international awards and citations which include: the International Hevesy Medal Award (2015) for excellence in Nuclear Sciences; Elected to the fellowship of the National Academy of Inventors (2015); One of the ‘25 Most Influential Scientists In Molecular Imaging in the Worldâ award by RT Image, the ‘Father of Green Nanotechnologyâ citation by the Nobel Prize Winner Norman Borlaug, Gauss Professorship— Hall of Fame— from the Gottingen Academy of Sciences, ‘Outstanding Scientists Fellowsâ award and induction as a Fellow of the Academy of Science, St Louis— one of the oldest scientific academies of the world and many more. In 2013, Dr. Katti was elected as a fellow of the American Association for the Advancement of Science with a citation “for distinguished contributions encompassing nanoscale chemistry, particularly for groundbreaking discoveries enabling application of nanotechnology concepts for biomedical applications”. His unprecedented discovery of the production of tumor-specific gold nanoparticles through 100% green processes has been cited as the Editorâ s choice in Nature, Future Medicine, in Science (AAAS), in Popular Science, by the Discovery Channel and has been highlighted in scientific/medical programs of the British Broadcasting Corporation (BBC, London)

Dr. Katti's research is focused on unraveling fundamentals of science and apply those principles and concepts to developing new chemical species at the macro and nano scales. In the nanodomain, he is interested in exploring chemical, biophysical, magnetic and photophysical properties, that are unique to specific nanoparticulates, toward the design and development of sophisticated diagnostic and therapeutic agents. Targeted nanoparticles are being utilized in the detection of diseases at the cellular/sub cellular levels while radiochemical and X ray absorption properties of gold nanoparticles, embedded selectively within tumor cells/sites, are being applied for effective therapy of breast, liver, lung, oral, prostate and pancreatic cancers. Drug discovery approaches are built around clinical translation motif as Dr. Katti strongly believes that discoveries should translate into value added products to ultimately serve humanity. Green nanotechnology is at the focal point of Dr. Katti's approach to pursuing research in nanotechnology as he strongly believes in the total elimination of toxic chemicals either for the synthesis or as byproducts in the production of engineered nanoparticles. Toward this end, phytochemicals occluded within plants, herbs or from various sources from mother nature are being used in developing 100% green processes for the development of nano constructs for use in a plethora of medical, agricultural, hygienic and technological applications

Dr. Burton Altura is currently serving as Professor of Medicine at New York University School of Medicine, USA

Role of magnesium, sphingolipids and lipid messengers in vascular biology and disease processes, such as stroke, diabetes mellitus and atherogenesis

At the NCL, Dr. Dobrovolskaia directs characterization related to a nanomaterials' interaction with components of the immune system. She monitors acute/adverse effects of nanoparticles as they relate to the immune system, both in vitro and in animal models. Dr. Dobrovolskaia is also responsible for the development, validation and performance qualification of in vitro and ex vivo assays to support preclinical characterization of nanoparticles, and for monitoring nanoparticle purity from biological contaminants such as bacteria, yeast, mold and endotoxin. Additionally, she leads structure activity relationship studies aimed at identifying the relationship between nanoparticle physicochemical properties and their interaction with macrophages, components of the blood coagulation cascade, and complement systems. Prior to joining the NCL, Dr. Dobrovolskaia worked as a Research Scientist in a GLP laboratory at PPD Development, Inc. in Richmond, VA. She was responsible for the design, development and validation of bioanalytical ligand-binding assays to support pharmacokinetic and toxicity studies in a variety of drug development projects. She received her M.S. degree from the Kazan State University in Russia, her Ph.D. from the N.N. Blokhin Cancer Research Center of the Russian Academy of Medical Sciences in Moscow, Russia, and completed two postdoctoral trainings in immunology at the National Cancer Institute in Frederick, MD and the University of Maryland in Baltimore, MD. Her areas of expertise include cell signaling, innate immunity, immunogenicity and analytical methodology.

Her areas of expertise include cell signaling, innate immunity, immunogenicity and analytical methodology.

Ghulam Ahmad Shakeel Ansari is a Professor in the University of Texas Medical Branch, USA. He received his PhD from Aligarh Muslim University in India and post doctoral fellowship from University of Texas Medical Branch in USA. He has more than 120 publications and has written more than 5 book chapters. He also received many honors and awards.

The University of Texas Medical Branch

Dr. Chuanshu Huang is currently a Professor, the Department of Environmental Medicine; Professor, Department of Biochemistry and Molecular Pharmacology Environmental Medicine Deputy Director

Signal transduction is involved in cellular function, tumor promotion, and nutrient chemo-prevention. Reactive oxygen species (ROS) are involved in cellular signaling and cancer development. Molecular mechanism of anti-cancer nutrients; Environment and carcinogenesis; |Signal transduction involved in cellular function, tumor promotion and nutrient chemo-prevention. Reactive oxygen species (ROS) are involved in cellular signaling and cancer development. Molecular mechanism of anti-cancer nutrients; Environment and carcinogenesis; |Signal transduction involved in cellular function, tumor promotion and nutrient chemo-prevention. Reactive oxygen species (ROS) are involved in cellular signaling and cancer development. Molecular mechanism of anti-cancer nutrients; Environment and carcinogenesis; |Signal transduction involved in cellular function, tumor promotion and nutrient chemo-prevention. Reactive oxygen species (ROS) are involved in cellular signaling and cancer development. Molecular mechanism of anti-cancer nutrients; Environment and carcinogenesis;

Amr Amin has completed his PhD at University of Illinois at Chicago, and received a post-doctoral training in the field of molecular genetics at the University of Pennsylvania School of Medicine. He started his academic career at UAE University where he serves now as a Full Professor of Cell Biology. Amr’s research focuses on ways to control cancer, particularly liver cancer. He published many research articles and reviews and serves as reviewer and as an editorial member of many specialized peer-reviewed journals. He is also a member of many specialized societies and the sole recipient of multiple national and international scientific awards.

Biological application of nanotechnology Biological applications of MRI and CT Cancer Biology Cell Biology Preventive medicine

Marcelo L. Larramendy, Ph.D., serves as Professor of Molecular Cell Biology at the School of Natural Sciences and Museum (National University of La Plata, Argentina). Appointed Senior Researcher of the National Scientific and Technological Research Council of Argentina. Former Member of the Executive Committee of the Latin American Association of Environmental Mutagenesis, Teratogenesis and Carcinogenesis. Author of more than 470 contributions, including scientific publications, research communications and conferences worldwide. Recipient of several national and international awards. Prof. Larramendy is a regular Lecturer at the international A. Hollaender Courses organized by the IAEMS and former guest scientist at NIH (USA) and University of Helsinki, (Finland). He is expert in Genetic Toxicology and is, or has been, referee for more than 30 international scientific journals. Member of the International Panel of Experts at the International Agency for Research on Cancer (IARC, WHO, Lyon, France) in 2015 for the evaluation of DDT, 2,4-D and Lindane. Presently, Prof. Dr. Larramendy is Head of the Laboratory of Molecular Cytogenetics and Genotoxicology at the UNLP.

Marcelo L. Larramendy’s fields of research interest include genotoxicity, Teratogenesis and Carcinogenesis. His areas of expertise include Molecular Cytogenetcis, Genetic Toxicology and Ecotoxicology.

Dr. Bluth practices clinical pathology. His expertise includes biomarker discovery and utility, transfusion medicine, artificial blood/blood alternatives, and translational medicine and commercialization. Dr. Bluth is specifically responsible for the transfusion service.

Dr. Bluth�s research interests covers a broad scope including immunology/inflammation, pancreatology, biomarker discovery, glycolipid based anti-inflammatory therapy, role of IgE in viral diseases and cancer, and blood derived stem cell propogation. Dr. Bluth is responsible for the education and training involved in the medical, basic science and translational research in the department. In addition to scholarly peer-reviewed publications, Dr. Bluth served as an Associate Editor of McPherson and Pincus: Henry�s Clinical Diagnosis and Management by Laboratory Methods (for 21st Ed and 22nd ed). He is the Editor in chief/founding editor of the Journal of Pharmacogenomics and Personalized Medicine and the Journal of Blood Medicine (Dove Medical Press � Auckland, New

Yazen M Alnouti is an Assistant Professor in the Department of Pharmaceutical Sciences, University of Nebraska Medical Center. He worked as a Research Assistant Professor in the Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center. he received his Post Doctorate from University of Kansas Medical Center. He was selected by Selected by “Who’s Who in America” as a scientist with outstanding achievements in the year 2009. He has a Professional membership in American Association of Colleges of Pharmacy (AACP). He experienced as a Teaching & Research Assistant in the College of Pharmacy, University of Georgia. His highlights of Research expertise include Drug Metabolism and Disposition, High-Throughput Bioanalytical Chemistry and Pharmacokinetics.

application of bioanalytical chemistry, in vitro models such as microsomes and stably-transfected cell lines, and in vivo animal models such as knock-out mice, to support ADMET (absorption, distribution, metabolism, excretion, and toxicity) and pharmacokinetics studies.

Hideo Nakayama was the Chief Dermatologist in Tokyo Saiseikai Central Hospital from 1970 to 1995. He was the Visiting Lecturer of Keio University, School of Medicine, from 1973 to 1995, Chief Dermatologist and Allergologist at Nakayama Dermatology Clinic from 1995 to 2015. He has graduated from Keio University, School of Medicine in 1961. Currently, he is the Advisor Doctor in Meguro Chen Dermatology Clinic (Tokyo). He has discovered new allergens, such as palladium,benzyl salicylate, R-219 (D&C R-31), ylang-ylang oil, ?-acaridial, etc., and developed new treatment systems by allergen control with pigmented cosmetic dermatitis, textile dermatitis, dental metal allergy and atopic dermatitis

Dermatology

conferenceseries Home About Us Journals Conferences Abstract Registration Technical Program Venue & Hospitality Sponsors / Exhibitors Awards 20th World Congress on Toxicology and Pharmacology May 06-07, 2019 Radisson Hotel Narita, Tokyo, Japan Theme: Probing Novel Facts in Toxicology and Pharmacology Search 57 Days 22 Hours 39 Mins 49 Secs OCM for Toxicology Congress Series Conferences Organizing Committee OCM Member R. Ponampalam Senior Consultant Singapore General Hospital Singapore OCM Member Antonio Rodriguez Valencia Medical Expert and consultant Michoacán de Ocampo Mexico Student Ambassadors OCM Member Rishikesh K. Tiwari PhD Scholar University of Allahabad India Organizing Committee - Toxicology Congress 2018 OCM Member Aristidis M. Tsatsakis President EUROTOX Greece OCM Member Ahmad Khalil Professor Yarmouk University Jordan OCM Member Swamy KB Professor Lincoln University College Malaysia OCM Member Regina Mary R Auxilium College, India India Organizing Committee - Toxicology Congress 2017 OCM Member Hanan Ghantous President American College of Toxicology United States OCM Member Aristidis M. Tsatsakis President EUROTOX Greece OCM Member Wojciech Wąsowicz President Polish Society of Toxicology Poland OCM Member Songsak Srianujat President Asian Society of Toxicology Thailand OCM Member Dagmar Jírová Head of Department of Toxicology and Health Safety National Institute of Public Health Czech Republic OCM Member Swamy K B Professor Universiti Sultan Zainal Abidin Malaysia OCM Member Khaled Abbas Helmy Abdou Professor of Toxicology Beni Suef University Egypt OCM Member Medani P. Bhandari Professor of Natural Resources and Environment Arabian Gulf University Kingdom of Bahrain OCM Member Sahar Y. Ibrahim Issa Faculty of Medicine Alexandria University Egypt Organizing Committee - Toxicology 2016 OCM Member Thomas Slaga Professor University of Texas Health Science Center at San Antonio USA × Biography Dr. Thomas Slaga has more than 45 years of experience in studying the mechanisms of carcinogenesis and chemoprevention and directing and establishing research centers. He is currently a Professor in the Department of Pharmacology, Associate Director for Basic Research of the NCI designated Cancer Center, Director of the Texas Consortium of Chronic Disease Prevention and Director of the Regional Health Science Center at Edinburg. Dr. Slaga started an active leadership role when he became head of an interactive research program on carcinogenesis and chemoprevention at the Oak Ridge National Laboratory. Later he became Director of the UTMDACC-SP whose mission was multidisciplinary and interactive research on cancer causation and prevention. Dr. Slaga became Scientific Director at the AMC Cancer Research Center and Deputy Director of the University of Colorado Comprehensive Cancer Center. Dr. Slaga has an important leadership role nationally and internationally in carcinogenesis and cancer prevention having started the Journal of Molecular Carcinogenesis. He has served on many review committees such as a full member and chair of the Chemical Pathology Study Section, American Cancer Society review groups, Cancer Center review groups and program project review committees. He also served on several NIEHS, EPA and FDA review committees. Dr. Slaga also serves on the Board of Directors for the Aspen Cancer Conference and several scientific advisory committees. He has a very active and funded research program. Continuously funded since 1974, his research program is currently supported by several R01 grants. He has over 300 peer reviewed publications and over 200 invited review articles, book chapters and scientific books on cancer as well as a lay book entitled, "The Detox Revolution" which emphasizes the importance of diet, nutrition and phytonutrients in chronic disease prevention. OCM Member Bahie M. Abou-Donia Professor Duke University School of Medicine USA OCM Member Max Costa Professor New York University School of Medicine USA OCM Member Raghbir Athwal Professor Temple University School of Medicine USA OCM Member Mustafa I. Selim Professor Brody School of Medicine at East Carolina University USA OCM Member Amr Amin Professor United Arab Emirates University UAE OCM Member Alexei G. Basnakian Professor University of Arkansas for Medical Sciences USA OCM Member Marina A. Dobrovolskaia Senior Principal Scientist Nanotechnology Characterization Lab USA OCM Member Marcelo L. Larramendy Principal Researcher CONICET National University of La Plata Argentina OCM Member Kattesh V. Katti Curators’ Professor University of Missouri USA OCM Member G.A. Shakeel Ansari Professor The University of Texas Medical Branch USA OCM Member Martin H. Bluth Professor Wayne State University School of Medicine USA OCM Member Burton M. Altura Professor State University of New York Downstate Medical Center USA OCM Member Chuanshu Huang Professor New York University School of Medicine USA Conferences By Continents USA & Americas USA Canada Brazil Mexico Asia-Pacific & Middle East Australia China Hong Kong India Indonesia Japan Malaysia New Zealand Philippines Romania Singapore South Korea Taiwan Thailand UAE Europe & UK Austria Denmark Finland France Germany Italy Luxembourg Netherlands Norway Poland South Africa Spain Switzerland Turkey UK Ukraine Medical & Clinical Conferences Alternative Healthcare Cardiology Dentistry Dermatology Diabetes & Endocrinology Gastroenterology Healthcare Management Immunology Infectious Diseases Medical Medical Ethics & Health Policies Microbiology Neuroscience Nursing Obesity Oncology & Cancer Ophthalmology Palliativecare Pathology Pediatrics Physical Therapy Rehabilitation Psychiatry Radiology Reproductive Medicine & Women Healthcare Surgery Vaccines Conferences By Subject Agri, Food & Aqua Biochemistry Business & Management Chemical Engineering Chemistry EEE & Engineering Environmental Sciences Genetics & Molecular Biology Geology & Earth science Hematology Materials Science Nanotechnology Nephrology Nutrition Petroleum Pharma Marketing & Industry Pharmaceutical Sciences Physics Pulmonology Veterinary View Proceedings of Previous Conferences Toxicology Congress 2018 Proceedings Toxicology Congress 2017 Proceedings Toxicology 2016 Proceedings Toxicology 2015 Proceedings Mail us at Drop us an email for Program enquiry. toxicologycongress@conferenceseries.net Sponsors / Exhibiting / Advertising. toxicology@conferencesseries.org sponsorship@conferenceint.org General Queries. toxicologycongress@toxicologyconferences.org Contact us at USA - +1-650-889-4686 UK - +44-203-7690-972 WhatsApp Number - +44-203-7690-972 Toll Free For Japan -81-345780247 Toll Free For USA/Canada -1-800-216-6499 Toll Free For UK -0-800-098-8455 Be a member and support us Join Our Mailing List Suggest A Speaker Suggestions Invite Proposals Follow us B Authorization Policy By registering for the conference you grant permission to Conference Series LLC Ltd to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries. © 2013-2018 Conference Series LLC Ltd All Rights Reserved.

The research in Dr. Thomas Slaga's laboratory is focused on glucocorticoid hormones (GC), very potent inhibitors of physiological DNA synthesis in keratinocytes in vivo. These hormones are also very effective in preventing carcinogen- and tumor promoter-induced skin hyperplasia, inflammation, and mouse skin tumor formation when applied to skin together with a carcinogen or a tumor promoter. We and others have shown, however, that the GC do not affect the growth of either established papillomas, squamous cell carcinomas (SCC), or transformed keratinocytes in vitro. In addition, we recently found that the GC do not affect glucocorticoid-responsive genes in transformed keratinocytes both in vitro and in vivo. We have generated skin-targeted transgenic mice over-expressing the GR under the control of the keratin 5 (K5) promoter. These adult transgenic mice have impaired proliferative and inflammatory responses to skin tumor promoters. Our initial studies showed that the K5.GR transgenic animals are resistant to ras-induced tumorigenesis. The constitutively nuclear overexpression and activation of the GR in the epidermis dramatically inhibited skin tumor development in K5.GR/ras+ double transgenic mice in terms of number of animals that develop tumors, number of tumors per animal, and tumor size. In another study we plan to determine the mechanism(s) of synergistic action of the natural source compounds, known to inhibit one or more stages of skin carcinogenesis, i.e., initiation and promotion/progression. The concurrent topical and systemic (i.e., dietary) treatment with selected natural source inhibitors of different stages of skin carcinogenesis result in synergistic effects leading to more efficient prevention of skin cancer. The natural source inhibitors to be tested include ellagic acid, imperatorin from the family of coumarins, proanthocyanidin B-2-gallate, (-)-epigallocatechin from the family of green tea polyphenols, N-acetylcysteine, calcium D-glucarate, lycopene, carnosol and ursolic acid from rosemary extract, and resveratrol. We propose to initially utilize a number of very predictive short-term in vitro and in vivo tests in order to identify the mechanism(s) and to differentiate the potencies of selected inhibitors at various concentrations under standard conditions. The most effective compounds will then be studied in long-term tumor experiments utilizing a 7,12-dimethylbenz[a]anthracene (DMBA)-induced 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted multistage carcinogenesis model in SENCAR mice.

Raghbir Athwal has done his BSc Biology, MSc Genetic at the Punjab Agricultural University. He completed his PhD in Genetics at the University of Missouri. Dr. Raghbir Athwal has done his Postdoctoral fellowship in the Division of Human Genetics, Department of Pediatrics at the University of Missouri and in the Laboratory of Biochemistry at the Howard University Medical School. Dr. Raghbir Athwal has been research associate National Institutes of Health, National Cancer Institute. Currently, Dr. Raghbir Athwal is working as a Professor in the department of Pathology and Laboratory Medicine at the Temple University School of Medicine and Fels Institute for Cancer Research and Molecular Biology

The long term goal of our research is to elucidate molecular and genetic pathways involved in the regulation of normal cell growth leading to senescence, and their role in the development of cancer and cellular aging. Normal mammalian cells, unlike cancer cells, multiply only for a finite number of generations, and eventually enter a state of irreversible growth arrest, “the replicative senescence”. Applying a functional strategy, we have identified four cell senescence genes, three on chromosome 6q and one on 16q. The ectopic expression of one of the genes (SEN6A), cloned in a retroviral vector, induce senescence in ovarian and breast tumor cells, and lead to premature senescence in normal human fibroblasts. SEN6A is either rearranged or not expressed in many of the breast and ovarian tumor cells, suggesting that it plays a role in the etiology of breast and ovarian cancers. Further pursuit of our research includes delineation of mechanisms of SEN6A inactivation in tumor cells; and identifies signaling pathways involved in the functioning of SEN6A. Our preliminary observations revealed that SEN6A may be involved in DNA damage-repair response through a pathway related to the production of Reactive Oxygen Species (ROS). These finding evoked our interest to study genes associated with DNA damage – repair pathways in relation to cellular senescence. Signaling pathways that regulate cell senescence has gained significance as emerging targets for cancer therapy. In another project, we are investigating the molecular mechanisms of virus induced malignant transformation of human cells. These studies are driven by the hypothesis that immortalization of human cells requires the disruption of specific genes through viral integration. Using SV40 mediated immortalization of human fibroblasts as a model system; we have isolated a human DNA segment, corresponding to the viral insertion site. The introduction of this cloned human DNA segment, into SV40 immortalized cells, led to the restoration of normal cell growth pattern and senescence. Almost 100 percent of cervical cancer is positive for the presence of HPV virus. Future studies in this project are directed to identify human genes disrupted through HPV integration, and examine their role in the etiology of cervical cancer. The ultimate aim of our research is to identify molecular targets for diagnosis and therapeutic intervention of cancer.